In late 2011, Yale University combined 2 successful exisiting cores, Small Molecule Discovery Center and High Throughput Cell Biology, into a single core: Yale Center for Molecular Discovery (YCMD). YCMD was established to provide high-throughput and high-content screening and assay development, as well as medicinal chemistry services. YCMD works with individuals from Yale Cancer Center (YCC) and other Yale laboratories to design, optimize, and execute all phases of small molecule and siRNA screening in customized biochemical, cell-based, and model organism-based assays. YCMD synergizes existing technologies and expertise and helps expand the capabilities and impact of investigators? novel concepts by mining pathways or identifying small molecule leads in a cost-effective manner. As a YCC shared resource, YCMD offers services that span a range of investigator-driven goals and needs. During the most recent funding period, 49 laboratories have used YCMD. Thirty of these users (61%) were YCC members. This Shared Resource was most widely used by Developmental Therapeutics (DT), but nearly all of the YCC research programs benefited from this core. YCMD helped YCC members in basic and translational research address fundamental questions in biology. In pursuit of translational research, YCMD scientists discover novel small molecule probes that may serve as starting points for new therapeutics, to understand basic biological processes and to crystallize proteins in unique conformations that reveal their mechanisms of action. Crystal structures enable structure-based drug design to inform hypotheses for development of new molecules with increased binding, solubility, or attachment of linker groups.
The Specific Aims of YCMD are to: (1) Facilitate new lines of research for YCC members and other Yale faculty; (2) Support early-stage development for translational research programs; and (3) Make the YCMD suite of technologies required for assay development and high-throughput screening accessible to a wide user base.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016359-39S3
Application #
9772305
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Roberson, Sonya
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
39
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025
Wang, Shi-Yi; Long, Jessica B; Killelea, Brigid K et al. (2018) Associations of preoperative breast magnetic resonance imaging with subsequent mastectomy and breast cancer mortality. Breast Cancer Res Treat 172:453-461
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331

Showing the most recent 10 out of 675 publications